Loading stock data…
LUCD
$1.09+0.02 (+1.87%)
Market ClosedLast close May 1
Lucid Diagnostics Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Lucid Diagnostics Inc. in the Healthcare sector is trading at $1.09. The stock is currently near its 52-week low of $0.95, remaining 6.0% below its 200-day moving average. Technical signals show neutral RSI of 37 and bearish MACD signal, explaining why LUCD maintains its current current market pressure. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 37) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$1.09
Potential Upside
5%
Whystock Fair Value$1.14
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. It focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, prima...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$194.01M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.25
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-530.45%
Volume
Today's trading volume
786,134
Recent News
Lucid Diagnostics Inc (LUCD) Q4 2025 Earnings Call Highlights: Strong Test Volume Growth and ...
Lucid Diagnostics Inc (LUCD) reports a 29% increase in test volume and secures a key contract with the US Department of Veteran Affairs, setting the stage for future growth.
Lucid Diagnostics Inc. Q4 2025 Earnings Call Summary
Moby summary of Lucid Diagnostics Inc.'s Q4 2025 earnings call
Lucid Diagnostics Q4 Earnings Call Highlights
Lucid Diagnostics (NASDAQ:LUCD) reported higher fourth-quarter 2025 EsoGuard testing volume and revenue and highlighted progress on reimbursement initiatives, including a new U.S. Department of Veterans Affairs (VA) contract and ongoing discussions with Medicare and commercial payers. Fourth-quarte
Lucid Diagnostics (LUCD) Earnings Transcript
Joining me today on the call are Dr. Lishan Aklog, Chairman and CEO of Lucid Diagnostics Inc., along with Dennis M. McGrath, Chief Financial Officer. The press release announcing our business update and financial results is available on Lucid Diagnostics Inc.'s website. Please take a moment to read the disclaimers about forward-looking statements in the press release.
Lucid Diagnostics Inc. (LUCD) Reports Q4 Loss, Beats Revenue Estimates
Lucid Diagnostics (LUCD) delivered earnings and revenue surprises of -42.86% and +15.69%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?